4CPS-103 Second-generation tyrosin kinase inhibitors in front-line therapy. comparing responses

BACKGROUND: Second-generation tyrosine kinase inhibitors(2G-TKI) have increased considerably over the past few years. Despite good and maintained results with imatinib, 2G-TKI have shown a growing trend in their use due to their quick and deep response. However, there is no clear positioning between...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Eur J Hosp Pharm
Egile Nagusiak: Soto, CM Valencia, López-Sepúlveda, R, Artime-Rodríguez-Hermida, F, Herrera, S Guijarro, Villacañas-Palomares, MV, Gómez, P Nieto, Miguel, S Cortes-de
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Group 2018
Gaiak:
Section 4: Clinical pharmacy services
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535530/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.194
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak